Our Parkinson's Place: Parkinson’s disease treatment : QBRI expertise to help clinical trials

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Friday, April 28, 2017

Parkinson’s disease treatment : QBRI expertise to help clinical trials

April 28, 2017

Dr Omar M Ali El-Agnaf in his lab

A research team headed by Dr Omar El-Agnaf, acting executive director of Qatar Biomedical Research Institute (QBRI), one of Hamad Bin Khalifa University’s (HBKU) three national research institutes, has been selected by the Austrian biotechnology company, AFFiRiS AG, to evaluate selected parametres in clinical trials on an innovative anti-alpha-synuclein immunotherapy-based approach to treating Parkinson’s disease.

Research carried out by Dr El-Agnaf’s team of scientists that uses novel techniques to identify biomarkers of Parkinson’s disease in human blood and cerebral spinal fluid samples attracted the attention of AFFiRiS AG, a leading name in the field of developing immunotherapies that target chronic diseases with unmet medical needs.

AFFiRiS AG called upon the Qatar-based team to use the tools and expertise developed at HBKU to validate the target engagement of alpha-synuclein for the company’s first-of-its-kind Parkinson’s disease immunotherapy approach. The product has been developed in Europe by a team of scientists and its pre-clinical and clinical development has been supported by Michael J Fox Foundation.

Using the team’s novel analysis techniques, the researchers at HBKU will assess the product’s ability to engage with the target, alpha-synuclein. QBRI’s scientists will explore novel biomarkers discovered by them that facilitate early diagnosis and treatment of Parkinson’s disease and use the technique they have developed at HBKU to assess the magnitude of target engagement of this new immunotherapy-based compound.

Dr. El Agnaf’s group, based within QBRI’s labs within Education City in Doha, specialises in biomedical research that focuses on Parkinson’s disease and related neurodegenerative disorders, are also involved in the development of drugs that target the treatment of neurodegenerative diseases.

QBRI has established itself as a leading disease-focused research institute in the Middle East. Currently, QBRI operates three research centres that target different diseases: the Neurological Disorders Research Centre, the Cancer Research Centre, and the Diabetes Research Centre.

http://www.gulf-times.com/story/546094/Parkinson-s-disease-treatment-QBRI-expertise-to-he